Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer-Reference-Cited by-同舟云学术

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

Published:2015-11-02 Issue:12 Volume:106 Page:1714-1721
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kiyota Naomi¹,Schlumberger Martin²,Muro Kei³,Ando Yuichi⁴,Takahashi Shunji⁵,Kawai Yasukazu⁶,Wirth Lori⁷,Robinson Bruce⁸,Sherman Steven⁹,Suzuki Takuya¹⁰,Fujino Katsuki¹¹,Gupta Anubha¹²,Hayato Seiichi¹³,Tahara Makoto¹⁴

Affiliation:

1. Department of Medical Oncology and Hematology Kobe University Hospital Kobe Japan

2. Department of Nuclear Medicine and Endocrine Oncology Gustave Roussy and University Paris‐Sud Villejuif France

3. Department of Clinical Oncology Aichi Cancer Center Hospital Nagoya Japan

4. Department of Clinical Oncology and Chemotherapy Nagoya University Hospital Nagoya Japan

5. Department of Medical Oncology Cancer Institute Hospital of JFCR Tokyo Japan

6. Department of Hematology and Oncology Fukui Prefectural Hospital Fukui Japan

7. Department of Medicine Massachusetts General Hospital Boston Massachusetts USA

8. Kolling Institute of Medical Research University of Sydney Sydney New South Wales Australia

9. Department of Endocrine Neoplasia and Hormonal Disorders Division of Internal Medicine The University of Texas M.D. Anderson Cancer Center Houston Texas USA

10. Oncology Clinical Development Eisai Co., Ltd Tokyo Japan

11. Japan Biostatistics Eisai Co., Ltd Tokyo Japan

12. Clinical Pharmacology Eisai Ltd. Hatfield UK

13. Clinical Pharmacology Eisai Co., Ltd Tokyo Japan

14. Department of Head and Neck Medical Oncology National Cancer Center Hospital East Kashiwa Japan

Funder

Eisai Inc.

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link